

SKYEPHARMA PLC
Form 6-K
March 02, 2006

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March, 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

Edgar Filing: SKYEPHARMA PLC - Form 6-K

**Initial SkyePharma Response to Allegations
Made by North Atlantic Value Group**

LONDON, UK, 2 March 2006 -SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) notes the announcement made to

The allegations made in this statement are without substance. Once again the NAV group offers sha
SkyePharma forward. Instead the statement contains unsubstantiated claims linked tenuously to Cor
by the highest Corporate Governance standards and strongly resents any claims to the contrary.
SkyePharma will release a detailed response to all the allegations in its statement later today.

Shareholders are urged to take no action until they have seen the facts.

For further information please contact:

SkyePharma PLC

+44 207 491 1777

Michael Ashton, Chief Executive Officer

Peter Laing, Director of Corporate Communications

+44 207 491 5124

Sandra Haughton, US Investor Relations

+1 212 753 5780

Buchanan Communications

+44 207 466 5000

Tim Anderson / Mark Court

Notes for editors:

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery techn
and more effective drug formulations. There are now eleven approved products incorporating SkyePh
oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities
www.skyepharma.com.

*Certain statements in this news release are forward-looking statements and are made in reliance o
U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectation
statements are reasonable, it can give no assurance that these expectations will materialize. Bec
risks and uncertainties, actual results may vary significantly from those expressed or implied by
based upon a number of factors, which are described in SkyePharma's 20-F and other documents on f
cause differences between actual results and those implied by the forward-looking statements cont
without limitation, risks related to the development of new products, risks related to obtaining
for existing, new or expanded indications of existing and new products, risks related to SkyePhar
on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability to
maintain or expand market share in the face of changes in customer requirements, competition and
to regulatory compliance, the risk of product liability claims, risks related to the ownership an
risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to re
forward-looking statement to reflect events or circumstances after the date of this release.*

END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Edgar Filing: SKYEPHARMA PLC - Form 6-K

Name: Douglas Parkhill
Title: Company Secretary

Date: March 02, 2006